Solving Kids’ Cancer is proud to stand beside Fiona Govan and the entire DIPG community, following their incredible advocacy work calling for increased funding for research into the most difficult-to-treat childhood cancers.

We are delighted to have announced the first International Neuroblastoma Research Initiative award to be funded under our AMRC-accredited research funding process, which will see a targeted drug introduced to frontline treatment for children with the hope

Grant awarded to Children’s Hospital of Philadelphia (CHOP) and Gustave Roussy in Paris to support Phase 3 clinical trial, representing the first-ever collaboration between these North American and European neuroblastoma consortia.

Our CEO, Gail, reflects on 'Pandemic Fatigue' and the importance of celebrating success in the face of challenge.

This Autumn we are extremely busy with our ongoing International Neuroblastoma Research Initiatives.

Gail Jackson, CEO, launches her blog. Reflecting on personal resilience, our work and joining Solving Kids' Cancer as COVID hit.

The impact of COVID-19 has been serious and will have long-lasting consequences for medical research in the UK, not least because so much of our medical research is funded by charities.

The REDMAPP research study aims to develop a decision aid to support parents when their child has relapsed neuroblastoma by first gaining a greater understanding of how parents make a series of repeated treatment-related decisions.

Solving Kids’ Cancer, with Neuroblastoma UK, has awarded a grant of £609,762.40 to enable the SIOPEN High-Risk Neuroblastoma Clinical Trial 2 (HR-NBL2) to open in the UK, it is anticipated to open in early 2021.